A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy

Combination therapies simultaneously inhibiting different therapeutic targets in cancer is challenged by individual pharmacokinetic profiles. Here, the authors generate an orally provided multi-targeted kinase inhibitor that is lymphatic absorbed and increases survival in a murine model of myelofibr...

Full description

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Brian D. Ross, Youngsoon Jang, Amanda Welton, Christopher A. Bonham, Dilrukshika S. W. Palagama, Kevin Heist, Jagadish Boppisetti, Kasun P. Imaduwage, Tanner Robison, Leah R. King, Edward Z. Zhang, Cyrus Amirfazli, Kathryn E. Luker, Winston Y. Lee, Gary D. Luker, Thomas L. Chenevert, Marcian E. Van Dort
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-08-01
Online Access:	https://doi.org/10.1038/s41467-022-32486-8